In search of a real "targeted" therapy for thyroid cancer.
Publication/Presentation Date
4-1-2012
Abstract
Over the past 5 years, patients with progressive radioactive iodine-refractory thyroid cancer have responded to "targeted" multikinase inhibitors, which inhibit angiogenesis and not the tumor cell. Here, selumetinib targets the mitogen-activated protein kinase pathway in papillary thyroid carcinoma and shows limited single-agent activity in the patients with tumors that harbor the (V600E)BRAF mutation.
Volume
18
Issue
7
First Page
1827
Last Page
1829
ISSN
1557-3265
Published In/Presented At
Brose M. S. (2012). In search of a real "targeted" therapy for thyroid cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 18(7), 1827–1829. https://doi.org/10.1158/1078-0432.CCR-12-0153
Disciplines
Medicine and Health Sciences
PubMedID
22451620
Department(s)
Hematology-Medical Oncology Division
Document Type
Article